Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.62) by 4.84 percent. This is a 20.27 percent increase over losses of $(0.74) per share from the same period last year.
Semtech’s Incoming CEO’s Long-Term Model and Potential Divestures have Upside: Analyst
Needham analyst Quinn Bolton upgraded Semtech Corp (NASDAQ: SMTC) from Hold to Buy and a